The Institute For Cancer Research

UEI FF1XVJMDYVR1 · PA · SAM.gov record ↗

$-17K

FY2025 obligations

Contract awards

Jan 24, 2019

First action

Jul 20, 2026

Latest action

Obligations by agency

Department Of Health And Human Services$-17K

Obligations by NAICS

541714 · Research And Development In Biotechnology (Except Nanobiotechnology)$0
541715 · Research And Development In The Physical, Engineering, And Life Sciences (Except Nanotechnology And Biotechnology)$-17K

Monthly obligations

Oct 24

Feb 25

Jul 25

Nov 25

Dec 25

Jan 26

Apr 26

May 26

Jun 26

Jul 26

Contracts ending within 18 months (recompete watch)

75N91022F00002 ↗$0
BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER
Ends
Nov 16, 2026
Started
May 17, 2022
Agency
National Institutes Of Health
NAICS
541714
75N91023F00003 ↗$0
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS TASK ORDER TITLE: SULFORAPHANE FOR THE PREVENTION OF MALIGNANT MESOTHELIOMA
Ends
May 1, 2027
Started
May 2, 2023
Agency
National Institutes Of Health
NAICS
541714
75N91022F00001 ↗$0
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS TASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIATED COLORECTAL CANCER IMMUNOPREVENTION
Ends
May 13, 2027
Started
Jun 14, 2022
Agency
National Institutes Of Health
NAICS
541714
75N91023F00001 ↗$0
COLORECTAL CANCER (CRC) PREVENTION BY UROLITHIN A IN RODENT CRC MODELS
Ends
Jul 8, 2027
Started
Jul 9, 2023
Agency
National Institutes Of Health
NAICS
541714

PIID	Description	Agency	NAICS	Obligated	Start	End
75N91022F00002 ↗	BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER	National Institutes Of Health	541714	$0	May 17, 2022	Nov 16, 2026
75N91023F00003 ↗	PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS TASK ORDER TITLE: SULFORAPHANE FOR THE PREVENTION OF MALIGNANT MESOTHELIOMA	National Institutes Of Health	541714	$0	May 2, 2023	May 1, 2027
75N91022F00001 ↗	BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS TASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIATED COLORECTAL CANCER IMMUNOPREVENTION	National Institutes Of Health	541714	$0	Jun 14, 2022	May 13, 2027
75N91023F00001 ↗	COLORECTAL CANCER (CRC) PREVENTION BY UROLITHIN A IN RODENT CRC MODELS	National Institutes Of Health	541714	$0	Jul 9, 2023	Jul 8, 2027

Largest awards

75N91024D00003 ↗$0
PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM
Ends
—
Started
Jan 24, 2024
Agency
National Institutes Of Health
NAICS
541714
75N91022F00003 ↗$0
TASK ORDER TITLE: MICROBIAL METABOLITE MIMICRY, A NANO-DRUG FOR COLON CANCER PREVENTION PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS
Ends
Jun 13, 2026
Started
Sep 14, 2022
Agency
National Institutes Of Health
NAICS
541714
75N91022F00002 ↗$0
BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER
Ends
Nov 16, 2026
Started
May 17, 2022
Agency
National Institutes Of Health
NAICS
541714
75N91023F00003 ↗$0
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS TASK ORDER TITLE: SULFORAPHANE FOR THE PREVENTION OF MALIGNANT MESOTHELIOMA
Ends
May 1, 2027
Started
May 2, 2023
Agency
National Institutes Of Health
NAICS
541714
75N91022F00001 ↗$0
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS TASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIATED COLORECTAL CANCER IMMUNOPREVENTION
Ends
May 13, 2027
Started
Jun 14, 2022
Agency
National Institutes Of Health
NAICS
541714
75N91023F00001 ↗$0
COLORECTAL CANCER (CRC) PREVENTION BY UROLITHIN A IN RODENT CRC MODELS
Ends
Jul 8, 2027
Started
Jul 9, 2023
Agency
National Institutes Of Health
NAICS
541714
75N91019D00022 ↗$0
EO 14398 PREVENT PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS
Ends
—
Started
Jan 24, 2019
Agency
National Institutes Of Health
NAICS
541714
75N92E21P00142 ↗$-17K
THE ELNITSKI LAB IS PURCHASING NORMAL, LIVER, AND PROSTATE CANCER PATIENT PLASMA.[21-004028]
Ends
May 2, 2021
Started
May 2, 2021
Agency
National Institutes Of Health
NAICS
541715

PIID	Description	Agency	NAICS	Obligated	Start	End
75N91024D00003 ↗	PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM	National Institutes Of Health	541714	$0	Jan 24, 2024	—
75N91022F00003 ↗	TASK ORDER TITLE: MICROBIAL METABOLITE MIMICRY, A NANO-DRUG FOR COLON CANCER PREVENTION PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS	National Institutes Of Health	541714	$0	Sep 14, 2022	Jun 13, 2026
75N91022F00002 ↗	BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER	National Institutes Of Health	541714	$0	May 17, 2022	Nov 16, 2026
75N91023F00003 ↗	PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS TASK ORDER TITLE: SULFORAPHANE FOR THE PREVENTION OF MALIGNANT MESOTHELIOMA	National Institutes Of Health	541714	$0	May 2, 2023	May 1, 2027
75N91022F00001 ↗	BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS TASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIATED COLORECTAL CANCER IMMUNOPREVENTION	National Institutes Of Health	541714	$0	Jun 14, 2022	May 13, 2027
75N91023F00001 ↗	COLORECTAL CANCER (CRC) PREVENTION BY UROLITHIN A IN RODENT CRC MODELS	National Institutes Of Health	541714	$0	Jul 9, 2023	Jul 8, 2027
75N91019D00022 ↗	EO 14398 PREVENT PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS	National Institutes Of Health	541714	$0	Jan 24, 2019	—
75N92E21P00142 ↗	THE ELNITSKI LAB IS PURCHASING NORMAL, LIVER, AND PROSTATE CANCER PATIENT PLASMA.[21-004028]	National Institutes Of Health	541715	$-17K	May 2, 2021	May 2, 2021